| TCH-AML001 | AML001 | Acute myeloid leukemia | White | 1.33 | Male | Diagnosis | 405200 | 0 | No | 3 | Not Reported | 47,XY,+8[20].ish
ins(10;11)(p1?3;q23q23)(10pter+,wcp10+,wcp11+,5'MLL+;wcp11+,
5'MLL-,3'MLL+,11qter+) | 90 | 2CDA,AAML1031 ADE10,ADE8,AE,Erwinia,HDAC,Ida,MTX,Multiple intensive regimens,PEG-asp,VCR,dexamethasone |
| TCH-AML002 | AML002 | Acute myeloid leukemia | Black or African American | 20.04 | Female | Refractory | Unknown | Not Reported | No | Unknown | Not Reported | t(7;21), -17 | | Cytarabine,Fludarabine,Idarubicin,azacitidine,clo,decitabine,thiotepa,topotecan,venetoclax,venetoclax then DLI,vinorelbine |
| TCH-AML003 | AML003 | T-Acute myeloid leukemia | White,Hispanic or Latino | 7.12 | Male | Diagnosis | 63 | 0 | No | 2 | FLT3 Alteration | 46,XY,t(11;19)(q23;p13.1)[20] | 80 | FLAG,TVTC,Vyxeos,decitabine,vorinostat |
| TCH-AML004 | AML004 | Acute myeloid leukemia | White,Hispanic or Latino | 1.16 | Male | Diagnosis | 11450 | 2 | No | 1 | IDH2 | 46,XY,der(21)t(1;21)(q25;q22)[9]/46,XY[11] | 25 | ADE10,ADE8,Decitabine,Enasidanib,FLAG,Vorino,Vyxeos |
| TCH-AML005a | AML005+ | Acute myeloid leukemia | White,Hispanic or Latino | 16.7 | Male | Diagnosis | 348480 | 4 | No | 3 | RAS pathway | 47,XY,del(11)(q23q25),+21[20]; t(6;11) | 97 | ADE10,Azacitidine,Cytarabine,Decitabine,FLAG,Flud,Stem Cell Transplant,Vorino,azacitidine,venetoclax |
| TCH-AML005b | AML005+ | Acute myeloid leukemia | White,Hispanic or Latino | 16.7 | Male | Relapse | 348480 | 4 | No | 3 | RAS pathway | 47,XY,del(11)(q23q25),+21[20]; t(6;11) | | ADE10,Azacitidine,Cytarabine,Decitabine,FLAG,Flud,Stem Cell Transplant,Vorino,azacitidine,venetoclax |
| TCH-AML005c | AML005+ | Acute myeloid leukemia | White,Hispanic or Latino | 16.7 | Male | Refractory | 348480 | 4 | No | 3 | RAS pathway | 47,XY,del(11)(q23q25),+21[20]; t(6;11) | | ADE10,Azacitidine,Cytarabine,Decitabine,FLAG,Flud,Stem Cell Transplant,Vorino,azacitidine,venetoclax |
| TCH-AML006 | AML006 | Acute myeloid leukemia | Black or African American | 9.7 | Male | Refractory | 71600 | 1.5 | No | 2 | WT1,RAS Pathway | 46,XY,t(1;6;11)(q21;q27;q23)[19]/46,XY[1] | | 2CDA,ADE10 + GO,ADE8,Idarubicin,asparaginase,cytarabine,etoposide,mitoxantrone |
| TCH-AML007 | AML007 | Acute myeloid leukemia | White | 11.01 | Male | End of Induction | 100280 | 50 | No | 1 | PICALM-MLLT10,ETV6,Ras Pathway | 46,XY,t(3;12)(p21;p13),inv(9)(p11q13)c,t(10;11)(p12;q14)[19]/46,XY,inv(9)(p11q13)c[1].ish der(3)t(3;12)(12pter+),der(10)inv(11)(q23q23)t(10;11)(11qter+,5'KMT2A+,3'KMT2A+,10pter-,D10Z1+) | | ADE10,Aza,Cytarabine,FLAG,Flud,Stem cell transplant,decitabine,vorinostat |
| TCH-AML009 | AML009 | Acute myeloid leukemia | White,Hispanic or Latino | 17.48 | Female | Relapse | 750 | 0 | No | 1 | TP53 | 45,XX, t(11;19)(q23:p13.3),dic(12;13)(p12.p11.1) | | ADE10,ADE8,FLAG,Stem cell transplant,Vyxeos,azacitidine,cytarabine,decitabine,etoposide,vorinostat |
| TCH-AML010 | AML010 | Acute myeloid leukemia | White,Hispanic or Latino | 2.54 | Male | Diagnosis | 67800 | 0 | No | 1 | WT1 | 47, XY, +10 | 54 | ADE10,ADE8,asparaginase,cytarabine,etoposide,mitoxantrone |
| TCH-AML011 | AML011 | Acute myeloid leukemia | White | 19.72 | Female | Diagnosis | 39700 | 0.7 | No | 2 | FLT3 ITD or ALM,CEBPa or NPM1,WT1 | 46, XX | 89 | ADE10 + sorafenib,ADE8 + sorafenib,Stem cell transplant,cytarabine,etoposide + sorafenib |
| TCH-AML012a | AML012+ | Acute myeloid leukemia | White,Hispanic or Latino | 14.44 | Male | Diagnosis | 80800 | 5 | No | 1 | NUP98-NSD1,FLT3 ITD or ALM,WT1 | 47,XY,+8[17]/46,XY[3].ish t(5;11)(q35.3;p15.4) | 66 | |
| TCH-AML012b | AML012+ | Acute myeloid leukemia | White,Hispanic or Latino | 14.44 | Male | End of Induction | 80800 | 5 | No | 1 | NUP98-NSD1,FLT3 ITD or ALM,WT1 | 47,XY,+8[17]/46,XY[3].ish t(5;11)(q35.3;p15.4) | | |
| TCH-AML013 | AML013 | Acute myeloid leukemia | Black or African American | 12.91 | Male | Diagnosis | 148900 | Not Reported | No | 1 | Not Reported | 50,XY,t(6;11)(q27;q23),+der(6)t(6;11),+8,+19,+21[20]. | 90 | ADE10,ADE8,Decitabine,FLAG,TVTC,asparaginase,cytarabine,etoposide |
